Signum U.S. Healthcare, Inc. |
|
|

|
· Better quality of life during and after treatment: - no need for an invasive head frame - typically no hospital stays - few visits to hospital - short or no recovery periods · Treatment is available for tumors previously considered inoperable. -Reduces the risk of complications that are sometimes associated with conventional surgery · Dosage distributions adjusted to minimize radiation exposure to surrounding healthy tissue · Less pain · No blood loss · No scalpel · Mild sedation during treatment · Usually performed as an outpatient procedure |
|
More Frequently Asked Questions |
|
CyberKnife® technology is approved by the U.S. Food and Drug Administration (FDA) to treat tumors and lesions throughout the body. Signum intends to use the CyberKnife® to treat tumors of the brain, lung, spine, pancreas, liver, prostate, head and neck, including: · Benign tumours · Malignant tumors · Vascular malformations · Functional disorders |
|
What can the CyberKnife® treat? |
|
What are the benefits for patients? |
|
E-mail: info@signumhealth.com |